$67 million in Series A investment was received by Cambridge, Massachusetts-based biotechnology startup Delphia Therapeautics, which focuses in cancer medicines.
Investors
- Alexandria Venture Investments
- Nextech Invest
- Polaris Innovation Fund
- GV
Use of funds
The business plans to sue the money in order to use it for operations and R&D.
With the potential for considerable anti-tumor efficacy and longer-lasting patient benefit, Delphia Therapeutics is developing highly differentiated, first-in-class targeted cancer therapies by utilizing our activation lethality platform. To find the sites that induce activation lethality, the business combines investigations of inhibitor drug resistance, innovative functional genomic techniques, and tumor genetics.
Among the co-founders are:
- Bill Sellers, M.D., the head of the Harvard and MIT Broad Institute’s cancer program
- Mike Dillon, Ph.D., the former global head of cancer discovery chemistry at Novartis Institutes for BioMedical Research (NIBR) and former chief scientific officer of IDEAYA Biosciences
- Dr. Kevin Marks, the founder and CEO of Delphia, an entrepreneur-in-residence at GV, and the previous head of the NIBR cancer drug discovery site
About Delphia Therapeutics
A biotechnology startup called Delphia therapies is leading the way in activation lethality, a novel field of cancer therapies that targets the unexpected susceptibility of cancer to oncogene overactivation. The activation lethality platform developed by Delphia presents the possibility of developing first-rate targeted cancer medications that are both efficacious in and of themselves and capable of preventing the development of drug resistance to traditional targeted treatments.
